Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Godwin on Ongoing Clinical Trials for Men With Prostate Cancer

James L. Godwin, MD
Published: Tuesday, May 08, 2018



James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses ongoing trials for men with prostate cancer.

There are several ongoing trials looking at enzalutamide (Xtandi) in the frontline setting including ENZAMET and ARCHES. Additionally, the PEACE1 study is looking at a variety of combinations. Godwin says there will soon be head-to-head randomized data of docetaxel plus androgen-deprivation therapy (ADT) versus abiraterone acetate (Zytiga) plus ADT. The addition or absence of radiation therapy will depend on the patient population. These findings will add some extra data for physicians to consider when choosing therapy, states Godwin.

There are also trials looking at combinations of chemotherapy plus a next-generation androgen-targeting agent. An arm of the STAMPEDE trial is looking at the combination of upfront abiraterone and enzalutamide. There many ongoing phase III trials that will likely read out in the next few years and help inform the management of the disease, concludes Godwin.
 


James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses ongoing trials for men with prostate cancer.

There are several ongoing trials looking at enzalutamide (Xtandi) in the frontline setting including ENZAMET and ARCHES. Additionally, the PEACE1 study is looking at a variety of combinations. Godwin says there will soon be head-to-head randomized data of docetaxel plus androgen-deprivation therapy (ADT) versus abiraterone acetate (Zytiga) plus ADT. The addition or absence of radiation therapy will depend on the patient population. These findings will add some extra data for physicians to consider when choosing therapy, states Godwin.

There are also trials looking at combinations of chemotherapy plus a next-generation androgen-targeting agent. An arm of the STAMPEDE trial is looking at the combination of upfront abiraterone and enzalutamide. There many ongoing phase III trials that will likely read out in the next few years and help inform the management of the disease, concludes Godwin.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x